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Background: Asthma is a chronic respiratory disease, characterised by airways inflammation,
obstruction and hyperresponsiveness. Asthma control is the goal of asthma treatment, but
many patients have sub-optimal control. Exhaled NO and exhaled breath condensate (EBC)
NO metabolites (nitrites and nitrates) measurements are non-invasive tools to assess airways
inflammation. Our aim was to investigate the relationships between asthma control and the
above-named biomarkers of airways inflammation.
Methods: Thirty-nine non-smoking asthmatic patients (19 women) aged 50 (21e80) years per-
formed measurements of exhaled NO (FENO), EBC nitrates, nitrites and pH, and answered
Asthma Control Questionnaire (ACQ) and Asthma Control Test (ACT)-questionnaire.
Results: The ACT and ACQ score were strongly interrelated (rZ0.84, p< 0.001). No rela-
tionships between ACT or ACQ score and FENO were found (p> 0.05). EBC nitrates were nega-
tively related to ACT score (rZ 0.34, pZ 0.03) and positively related to ACQ score
(rZ 0.41, pZ 0.001) while no relation of EBC nitrites to either ACQ or ACT score was found
(p> 0.05).
Conclusion: EBC nitrates were the only biomarker that was significantly related to asthma
control. This suggests that nitrates, but not nitrites or FENO, reflect an aspect of airways
inflammation that is closer related to asthma symptoms. Therefore there is a potential role
for EBC nitrates in objective assessment of asthma control.
ª 2010 Elsevier Ltd. All rights reserved.of Medical Sciences, Clinical Physiology, Uppsala University, Akademiska sjukhuset, 75185 Uppsala,
46 18554079.
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Asthma is a chronic respiratory disease characterised by
reversible airway obstruction, airway inflammation and
hyperresponsiveness. Asthma control is sub-optimal in many
patients despite available effective therapies1 and interna-
tional guidelines for thediagnosis andmanagement,basedon
clinical features and lung function tests.2 The recent update
of international GINA guidelines2 suggests tailoring asthma
treatment to the level of disease control rather than severity.
Well-validated tools for assessing asthma control are avail-
able and two of the most widely used are Asthma Control
Questionnaire (ACQ)3 and Asthma Control Test (ACT).4 These
tools focus on the patient’s reported symptoms and addi-
tionally, lung function, in the case of ACQ. Neither symptoms
nor lung function alone seems to adequately reflect the
underlying level of airway inflammation.
The analysis of exhaled breath is a non-invasive method
to measure non-invasively airways inflammation in asthma
and other respiratory diseases. Nitric oxide (NO) levels are
increased in the air of asthmatic patients.5 Fraction of NO
in the exhaled air (FENO) is considered an indirect marker
of steroid-sensitive, eosinophilic airway inflammation and it
has been used to tailor inhaled steroid therapy in asthma.6
However the level of evidence so far available could not
recommend this approach for routine use.7
Exhaled breath condensate is another easy-to-use
technique and several markers in exhaled breath conden-
sate (EBC) have been related to airways’ inflammation.8 In
the airway surface liquid, NO reacts with oxygen forming
nitrite and nitrate, stable-end products of NO,9 which can
be measured in the EBC8 and might reflect NO formation in
the airways. EBC pH can be measured reliably10 and the
information regarding acidification of airways is regarded as
relevant to asthma pathophysiology.11
Increased levels of FENO and EBC nitrate, nitrite and sum
of nitrite and nitrate (NOx) are reported in asthmatic
subjects, when compared to healthy controls.12,13 There are
however fewer studies analysing the relation between these
markers and asthma control. No relation between exhaled
NO and asthma control is reported in cross-sectional stud-
ies.14e17 Peripheral airways inflammation, measured as
increased alveolar NO, has been related to poor asthma
control with contradictory results.17e19 The few studies that
analysed the relation between nitrogen oxides in EBC and
asthma control report contradictory results.20e22 No clear
relationship has been established between EBC pH and
asthma severity23e25 and no studies have reported a rela-
tionship between lower airways pH and poor asthma control.
The main aim of this study was to investigate the relation-
ships between EBCNOmetabolites, nitrite and nitrate, EBC pH
and asthma control. A secondary aim was to study the rela-
tionships between exhaledNO, and its estimated contributions
frombronchialandalveolarcompartment,andasthmacontrol.
Material and methods
Study subjects
Thirty-nine non-smoking consecutive patients (19 women)
aged 21e80 years (median age 50 years) with previouslydiagnosed asthma were included in the study. All patients
were coming for regular follow-up in the outpatient clinic
of Dept. of Allergology of Mauriziano Hospital, Turin, Italy
between November 2008 and July 2009.
Exhaled NO measurements
Exhaled NO was measured at 50, 100 and 200 mL/s with
a chemiluminescence analyser (NIOX, Aerocrine AB, Solna,
Sweden), according to current recommendations.26 Esti-
mation of alveolar and bronchial contributions to exhaled
NO was done by the slopeeintercept model27 using all the
above mentioned flow-rates in 29 of the 39 subjects. Of
those subjects, three had negative values of alveolar NO,
leaving 26 subjects for further analyses. Alveolar NO was
also calculated after adjustments for axial diffusion,
according to Kerckx et al.28
Exhaled breath condensate
Exhaled breath condensate was collected with the R Tube
EBC collection system (Respiratory Research, Inc, Charlot-
tesville, Virginia, USA). EBC collections were obtained after
thorough rinsing of mouth with water, at an initial
condenser temperature of 20 C, for 10 min. Samples
were store at 80 C until assays, which were performed
within 2 weeks of collection.
The pH of EBC was assayed immediately potentiometri-
cally with a glass microelectrode before and after bubbling
200 ml of the sample with argon at 350 mLmin1 until pH
reading was stable, as previously described.11
A modified anion chromatographic technique for nitrate
(NO2) and nitrite (NO3) determinations, described in
a previous publication, was used for measurements of NO2
and NO3 in EBC.
29 Briefly, liquid chomatograph (Dionex,
Sunnyvale, CA) equipped with a suppressed conductivity
detector and an autosampling injector were used. The
anion separator was an AG-4A-SC precolumn connected
with an AS-4A column (Dionex). The eluent was an aqueous
1.28/1.60 mmol/L of sodium carbonate/bicarbonate solu-
tion flowing at 1.5 mL/min. Twenty-microlitre aliquots of
EBC samples were injected into the column without pre-
treatment.
The intra-assay variability of the method (for NO2 and
NO3 detection), assessed by using the coefficient of varia-
tion, is 7 1.2%.29
ACQ
ACQ3 is a tool to assess asthma control which consists of 7
items: 6 questions, 5 related to symptoms during the last
week and one related to the use of short-acting beta2
agonists, and the seventh item is an objective measure e a
spirometric assessment (FEV1% predicted). Each item has 7
alternatives of answer, scored from 0 to 6. The ACQ score
is the mean of all these individual answers and therefore,
it ranges also from 0 to 6 with higher scores standing for
poorer control of asthma. A score of 0.75 has been
associated with “well-controlled” asthma while a score
1.5 has been associated with “not well-controlled”
asthma.30
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Asthma control test is a questionnaire developed to assess
asthma control.4 It consists of 5 questions, each with a 5
point scale from 1 (reporting all the time or very frequent
the respective symptom) to 5 (never reporting the respec-
tive symptom). Therefore, the total ACT score is between 5
and 25, with a lower score standing for poorer controlled
asthma. An ACT score 20 reflects well-controlled asthma.4
Lung function
Measurements of lung function were done with a water-
sealed spirometer (Biomedin, Padua, Italy). The best of
three measurements was automatically chosen by soft-
ware. The parameters of interest were FEV1, FEV1/FVC-
ratio, FEF25e75%.
Statistics
Statistical analyses were performed using STATA 10 soft-
ware (Stata Corp., Texas, USA). Values are presented as
median (range) and non-parametric statistics methods
(Spearman’s rank correlation test and ManneWhitney U-
test) have been used.
A p-value of <0.05 was considered statistically
significant.
Ethics
Informed and written consent was obtained from all
participating patients and the protocol was approved by
Local Ethics Committee.
Results
The characteristics of the 39 included asthmatic subjects
are described in Table 1.
Asthma control in the studied population
The ACT score (median (range)) was 22 (8, 25) and the ACQ
score (median (range)) was 0.71 (0, 3.86). The ACT and ACQTable 1 Patients’ characteristics.
Age (median (range)) 50 (21e80)
Females (N (%)) 19 (49%)
Atopy (N (%)) 30 (77%)
Inhaled steroid therapy (N (%))
No therapy 2 (5%)
<400 mga 15
400e800 mga 9
800e1200 mga 9
>1200 mga 4 (10%)
Oral steroids (N (%)) 2 (5%)
Rhinitis (N (%)) 32 (82%)
Chronic rhinosinusitis (N (%)) 22 (56%)
Nasal polyps (N (%)) 14 (36%)
a Equivalent budesonide dose.score were strongly related (rZ0.84, p< 0.001) (Fig. 1).
The relation was similar in subjects with steroid doses
<400 mg budesonide (rZ0.84, p< 0.001) (open circles)
and steroid doses 400 mg budesonide (rZ0.84,
p< 0.001) (closed diamonds).
Asthma control and FENO
FENO levels at the exhalation flow-rate of 50 mL/s were
ranging from 14 to 173 ppb, with a median value of 35 ppb.
No relation between ACQ or ACTscore and FENO at any of the
measured flow-rates and alveolar and bronchial contribu-
tions to exhaled NO was observed (all p-values> 0.05). No
differences were observed when adjusting the alveolar NO
for trumpet shape of the airways and axial diffusion.
Asthma control and lung function
Significant correlations were observed between asthma
control and spirometric parameters recorded in the study
(Table 2).
Asthma control and EBC markers
EBC pH ranged between 6.55 and 7.33 with a median value
of 7.07. No relation between ACQ score or ACT score and
EBC pH was found (both p-values> 0.05).
EBC NO3 ranged from 1.8 to 17 mM (median 6.5 mM) and EBC
NO2 ranged from 0.06 to 3.11 mM (median 0.68 mM). EBC NO3
were negatively related to ACT score (rZ0.34, pZ 0.03)
and positively related to ACQ score (rZ 0.41, pZ 0.001)
(Fig. 2A and B). No relation of EBC NO2 to either ACT score
(pZ 0.43) or ACQ score (pZ 0.43) was found (Fig. 2C and D).
Stratifying the subjects after the doses of inhaled steroids
used,wecouldobserve that the relationshipsbetweenEBCNO3
andACTorACQscoreweresignificantonly in subjects onadose
of inhaled steroids of at least 400 mg budesonide (rZ0.56,
pZ 0.004 for ACT; and rZ 0.58, pZ 0.003 for ACQ).
Using the sum of nitrite and nitrate, nitrogen oxides (NOx),
significant relationships could be shown with the ACT scoreFigure 1 Correlation between ACQ and ACT scores. Closed
diamonds represent subjects on steroid doses <400 mg bude-
sonide while open circles represent subjects on steroid doses
400 mg budesonide.
Table 2 Relationships between asthma control (measured
as either ACQ or ACT score) and lung function parameters.
Results are presented as Spearman r (p-value).
ACQ score ACT score
FEV1 (% pred) 0.61 (p< 0.001) 0.47 (pZ 0.003)
Tiffeneau index 0.42 (pZ 0.008) 0.40 (pZ 0.01)
FEF25e75 (% pred) 0.49 (pZ 0.001) 0.41 (pZ 0.01)
1010 A. Malinovschi et al.(rZ0.32, pZ 0.05) and ACQ score (rZ 0.36, pZ 0.02).
Similarly, this relation was found only in subjects on a dose of
inhaled steroids of at least 400 mg budesonide (rZ0.46,
pZ 0.02 for ACT; and rZ 0.46, pZ 0.02 for ACQ score).
The above reported results for nitrate were confirmed
also when comparing the subjects with a good control of
asthma vs those not controlled by means of ACT (pZ 0.008)
or ACQ (pZ 0.03). This relation was stronger in subjects on
doses of inhalation steroid 400 mg budesonide (pZ 0.002
for ACT and pZ 0.004 for ACQ score) (Fig. 3A and B). No
differences in EBC nitrite were found between subjects with
well-controlled vs not well-controlled asthma, either for all
subjects or after stratifying the subjects according to the
dose of inhaled budesonide (p> 0.30 for all) (see Fig. 3C and
D for subjects on high doses of inhalation steroids).
Effect of comorbidities and dose of inhaled steroids
on asthma control, FENO and EBC markers
Chronic rhinosinusitis was associated with higher ACQ
scores (pZ 0.05) and increased EBC NO3 levels (pZ 0.04),Figure 2 Correlation between EBC nitrate and ACT score (Panel A
between EBC nitrite and ACT score (Panel C) and ACQ score (Panel D
budesonide while open circles represent subjects on steroid doseswith no effect on EBC pH, EBC NO2, FENO levels or ACT
scores (all p-values> 0.2).
Rhinitis was associated with higher ACQ scores
(pZ 0.008) and lower ACT scores (pZ 0.03). No significant
increase of EBC NO3 (pZ 0.12) or significant associations
with EBC NO2, EBC pH and FENO (all p-values> 0.2) and
rhinitis were found.
The dose of inhaled steroids was not significantly asso-
ciated with ACQ and ACT scores, FENO, EBC NO3, EBC NO2,
EBC pH (all p-values> 0.30).
Discussion
The main finding of the present study was that exhaled
breath condensate nitrates concentration was related to
asthma control, assessed by means of two of the most
common used instruments, ACT and ACQ, either using
absolute scores, or validated cut-offs for well-controlled
asthma. On the other hand, no significant relationships
were found between asthma control and EBC pH, EBC
nitrites and exhaled NO, including its contributions from
peripheral and central airways.
The present study is one of the first studies looking
separately at nitrates and nitrites in EBC when assessing
their relation with asthma control. The NO metabolites in
EBC have been previously reported to be increased in
asthmatics compared to controls.12,13 However few studies
analysed separately nitrates,12 while most of the studies
have used a combination of nitrates and nitrites.13,20 It is
still a matter of debate which NO metabolite, measured in
EBC, nitrites or nitrates, is better related to airways) and ACQ score (Panel B), respectively, as well as correlations
). Closed diamonds represent subjects on steroid doses <400 mg
400 mg budesonide.
Figure 3 Box-plot of EBC nitrate (Panels A and B) and EBC nitrite (Panels C and D) in subjects on steroid doses 400 mg bude-
sonide with well-controlled and not well-controlled asthma, according to ACT scores (Panels A and C) or ACQ scores (Panels B and
D). Box-plot shows median (line), interquartile range (IQR) (box) and whiskers extend to 1.5 IQR. Values outside 1.5 IQR are
considered outliers (dots).
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studies,32 demonstrated that salivary nitrites concentration
may influence EBC nitrites, but not nitrates concentration,
suggesting that EBC nitrates, but not nitrites originate in
the lower airways. That nitrates and not nitrites concen-
trations are a more reliable marker of inflammation is also
suggested by previous observations that BAL nitrates and
not nitrites concentrations were related to airways
inflammation induced by segmental allergen challenge.33
Similarly, a recent study reported decrease of EBC
nitrates, but not nitrites after treatment with a new anti-
inflammatory drug.34 Moreover, increased EBC nitrates and
decreased EBC nitrites concentrations have been found to
be related to asthma severity in a Dutch study of asthmatic
children.21 In our study no significant relationship between
EBC nitrites and asthma control was found, in agreement
with previous reports.20,21,35
EBC pH too was not related to asthma control in our
patients. It is well known that exhaled breath condensate
pH reflects acidification of airways and this process has
been demonstrated to occur in acute asthma.11 In our
study, we could not observe any differences in EBC pH
between subjects with well-controlled and not well-
controlled asthma, in agreement with a study in children,
where EBC pH was not related neither to asthma severity
nor to asthma control.21 Therefore the acidic stress of the
airways is probably less important in stable asthma,
compared to acute asthma. Moreover, the majority of our
asthmatic patients had neutralealkaline pH values, sug-
gesting that no significant production of NO by nitrite
reduction due to acidic environment took place in the
airways of our asthmatic patients.11We did not find any significant relationship between
exhaled NO and asthma control and this is in line with
previous reports in adults and children,14e17 underlining
that symptoms and airway inflammation are two separate
aspects of asthma disease.36 However in longitudinal
studies,37,38 changes in FENO had been found to be related
to changes in ACQ scores, both in smoking and non-smoking
asthmatics. Alveolar NO has been reported in some small-
scale studies to be associated with more symptoms in both
adults and children39,40 and two larger studies reported
a significant association between poor asthma control and
increased alveolar NO in children.18,19 However these
results could not be confirmed in a recent large-scale pilot
study which enrolled both children and adults,17 question-
ing the value of alveolar NO as a marker of asthma control,
and our results agree with this study.
Exhaled breath condensate nitrates and nitrites
concentrations, EBC pH and exhaled nitric oxide were not
significantly interrelated in our patients, as previously
reported.20,32 This lack of correlations between exhaled NO
and its metabolites and airway pH is probably explained by
the complex biochemistry of nitrogen oxides in the airways,
and more specifically in the airway surface liquid (ASL).
While FENO mainly reflects the NO produced by epithelial
iNOS,41 the nitrogen oxides reflect not only the oxidization
of NO in the ASL, but they can also be generated through
peroxidase-mediated reactions.42 This might be an expla-
nation for divergent findings of normal NOx and low exhaled
NO levels in cystic fibrosis patients.43 Moreover a similar
divergent pattern, with increased nitrate and decreased NO
levels, has been observed immediately after allergen
challenge.44 Our findings reinforce the current view that
1012 A. Malinovschi et al.EBC nitrates are not an alternative to exhaled NO, but their
measurement should be considered complementary to the
exhaled NO measurements.45
Almost all of our patients were receiving inhaled steroid
therapy, which is well known to affect the levels of exhaled
NO, leading to a prompt, dose-dependent decrease.46
However, the effects of inhaled steroid treatment on EBC
nitrites and nitrates are not so well studied. EBC NOx
appear to decrease following inhaled steroid therapy, but
this effect is smaller than the effect on FENO and it was not
dose-dependent.46 NOx are increased in the nasal lavage of
patients with allergic rhinitis and these levels are not
affected by intranasal steroids.47 These observations might
suggest that EBC NOx concentration is poorly affected by
inhaled corticosteroids therapy, yielding another explana-
tion for the lack of correlation between FENO and EBC
nitrates and nitrites concentrations. We observed in our
material that the relation between EBC nitrate and asthma
control was driven by the group with more severe disease,
requiring higher steroid doses. This observation is intriguing
and suggests that similar FENO concentrations may not
necessarily indicate the same level of airway inflammation,
but instead may reflect decreased NO bioavailability from
increased NO oxidation.
Our asthmatics have a high prevalence of upper airway
diseases, reflecting the interest of our clinic in this area.48
Chronic rhinosinusitis was associated with poorer asthma
control in our patients, in agreement with the literature.49
No data exist on the levels of nitrates in EBC of patients
with CRS, who have been reported to have lower levels of
nitrate in nasal lavage.50
In conclusion, EBC nitrates concentration was the only
biomarker among those measured in the present study to
be significantly related to asthma control. This suggests
that EBC nitrates, but not EBC nitrites or FENO, reflect an
aspect of airways inflammation that is closer related to
asthma symptoms. These results reinforce the current view
that nitrogen oxides measurements in EBC provide infor-
mation on airway inflammation that is different from that
obtained from exhaled NO measurements. Particularly, our
results suggest a potential role for measuring EBC nitrates
in order to obtain an objective marker of asthma control in
asthmatic patients out of exacerbations.
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